Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941376 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
A Phase 2 study of Relapsing Polychondritis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06941376: Recruiting Phase 2 study of Relapsing Polychondritis, sponsored by University of Pennsylvania.
NCT06941376 is a Phase 2 study of Relapsing Polychondritis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 20 participants, below the 1,368-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941376, a Phase 2 study of Relapsing Polychondritis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
Primary Outcome
The proportion of subjects in remission at week 26
Conditions Studied
Interventions
- DRUG Methotrexate (MTX)
- DRUG Azathioprine (AZA)
- BIOLOGICAL Adalimumab
- BIOLOGICAL Infliximab
- BIOLOGICAL Tocilizumab
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06941376 shows while recruiting
NCT06941376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,368-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Relapsing Polychondritis appearing as the primary indexed condition, and to 5 interventions - of which Methotrexate (MTX) is the first listed.
NCT06941376 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06941376 about?
NCT06941376 is a clinical study titled "An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis". Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
What is the current status of trial NCT06941376?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08-01. Estimated completion is 2027-12.
What conditions does trial NCT06941376 study?
This clinical trial studies the following conditions: Relapsing Polychondritis.
What interventions are being tested in trial NCT06941376?
The interventions under investigation include: Methotrexate (MTX) (DRUG), Azathioprine (AZA) (DRUG), Adalimumab (BIOLOGICAL), Infliximab (BIOLOGICAL), Tocilizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06941376?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941376 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Polychondritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI